Brooks Laboratories Ltd

Brooks Lab. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Brooks Laboratories Ltd

₹ 45.0 19.98%
01 Apr 11:32 a.m.
brookslabs.net BSE: 533543 NSE: BROOKS
About

Incorporated in 2002, Brooks Laboratories Ltd is a pharmaceutical company working on contract basis catering to the critical care segment[1]

Key Points

Business Overview:[1]
BLL is an EU GMP & ISO 9001:2008 certified manufacturer and marketer of pharmaceutical formulations

Website BSE NSE
  • Market Cap ₹ 132 Cr.
  • Current Price ₹ 45.0
  • High / Low ₹ 166 / 36.3
  • Stock P/E 6.13
  • Book Value ₹ 39.3
  • Dividend Yield 0.00 %
  • ROCE -9.93 %
  • ROE -12.2 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company is almost debt free.
  • Stock is trading at 1.13 times its book value

Cons

  • Company has a low return on equity of -21.8% over last 3 years.
  • Contingent liabilities of Rs.75.7 Cr.
  • Earnings include an other income of Rs.19.2 Cr.
  • Promoter holding has decreased over last 3 years: -13.8%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025
15.30 12.61 15.70 24.32 21.75 17.72 17.93 20.79 20.52 23.32 25.51 23.45 16.57
23.85 16.31 19.61 25.42 25.12 27.25 19.85 24.20 22.02 24.58 22.38 20.93 15.84
Operating Profit -8.55 -3.70 -3.91 -1.10 -3.37 -9.53 -1.92 -3.41 -1.50 -1.26 3.13 2.52 0.73
OPM % -55.88% -29.34% -24.90% -4.52% -15.49% -53.78% -10.71% -16.40% -7.31% -5.40% 12.27% 10.75% 4.41%
0.45 0.03 0.05 0.09 0.16 0.65 0.07 0.20 0.03 0.62 7.15 6.13 5.32
Interest 0.75 0.18 0.17 0.19 0.21 0.27 0.16 0.32 0.28 0.26 0.30 0.28 0.16
Depreciation 2.33 0.44 0.44 0.44 0.43 0.46 0.40 0.43 0.38 0.39 0.39 0.39 0.39
Profit before tax -11.18 -4.29 -4.47 -1.64 -3.85 -9.61 -2.41 -3.96 -2.13 -1.29 9.59 7.98 5.50
Tax % -15.21% 0.00% 0.00% 0.00% 0.78% 0.00% 0.00% 0.00% 0.00% 13.95% 0.00% 0.00% 0.00%
-9.48 -4.29 -4.47 -1.64 -3.88 -9.61 -2.41 -3.96 -2.13 -1.46 9.58 7.98 5.50
EPS in Rs -1.92 -1.64 -1.71 -0.62 -1.48 -3.66 -0.92 -1.51 -0.81 -0.50 3.25 2.71 1.87
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
77 91 63 79 83 89
77 105 93 97 91 84
Operating Profit 1 -14 -30 -18 -8 5
OPM % 1% -16% -47% -22% -10% 6%
1 1 1 1 1 19
Interest 3 3 2 1 1 1
Depreciation 7 7 7 2 2 2
Profit before tax -9 -24 -38 -20 -10 22
Tax % 115% -19% -19% 0% 2%
-19 -19 -31 -20 -10 22
EPS in Rs -7.40 -4.31 -7.97 -7.46 -3.38 7.33
Dividend Payout % 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: -3%
TTM: 15%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 4%
TTM: 219%
Stock Price CAGR
10 Years: -6%
5 Years: -9%
3 Years: -16%
1 Year: -66%
Return on Equity
10 Years: %
5 Years: -21%
3 Years: -22%
Last Year: -12%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Sep 2025
Equity Capital 25 25 25 26 29 29
Reserves 54 63 49 39 69 86
31 25 7 6 8 8
52 83 29 19 18 16
Total Liabilities 162 196 110 90 124 140
108 110 15 14 14 13
CWIP 1 15 0 0 0 1
Investments 0 0 64 43 74 86
54 71 31 34 36 40
Total Assets 162 196 110 90 124 140

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
4 -37 -14 -10 3
-5 -25 0 0 -45
1 64 11 10 42
Net Cash Flow 0 2 -3 0 -0
Free Cash Flow -1 -62 -15 -10 2
CFO/OP 1,519% 261% 48% 56% -26%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 65 71 74 75 88
Inventory Days 178 157 80 60 61
Days Payable 233 159 165 97 90
Cash Conversion Cycle 9 68 -12 38 59
Working Capital Days -85 34 -37 34 43
ROCE % -16% -30% -25% -10%

Insights

In beta
Mar 2013 Mar 2014 Mar 2015 Mar 2018 Feb 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Total Permanent Employees
Number ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
Baddi Plant Capacity Utilization
% ・Standalone data
Sales Workforce Personnel
Number ・Standalone data
Market Authorizations Held
Number ・Standalone data
Number of Products/Brands
Number ・Standalone data
Installed Capacity (Vadodara Plant) - Carbapenems Injections
Million vials per annum ・Standalone data

Shareholding Pattern

Numbers in percentages

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
66.41% 66.41% 63.59% 63.59% 63.59% 63.59% 63.59% 59.06% 52.62% 52.62% 52.62% 52.62%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.02% 0.01% 0.05% 0.00% 0.01% 0.09%
0.00% 0.00% 2.46% 3.86% 3.86% 3.86% 3.86% 3.86% 10.38% 10.38% 10.38% 10.38%
33.59% 33.58% 33.94% 32.56% 32.55% 32.55% 32.53% 37.08% 36.95% 37.00% 37.00% 36.91%
No. of Shareholders 10,70911,21610,68610,02811,43211,54311,28210,52110,53710,31710,07810,532

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Right Issue

Credit ratings